Does thrombolytic therapy reduce all-cause mortality in patients with pulmonary embolism?
Thrombolytic therapy in pulmonary embolism reduces all-cause mortality but increases the risk of major bleeding and intracranial hemorrhage.
Among patients with pulmonary embolism, including those who were hemodynamically stable with right ventricular dysfunction, thrombolytic therapy was associated with lower rates of all-cause mortality and increased risks of major bleeding and ICH. However, findings may not apply to patients with pulmonary embolism who are hemodynamically stable without right ventricular dysfunction.
Chatterjee et al. (Tue,) studied this question.